×
S&P 500   3,754.18 (-1.86%)
DOW   30,453.70 (-2.07%)
QQQ   279.29 (-1.01%)
AAPL   138.42 (-0.37%)
MSFT   256.22 (-1.29%)
META   161.37 (+0.84%)
GOOGL   2,169.75 (-0.23%)
AMZN   110.10 (+0.49%)
TSLA   662.13 (-2.88%)
NVDA   144.95 (-0.19%)
NIO   21.24 (-0.56%)
BABA   114.64 (-1.17%)
AMD   73.14 (-0.72%)
MU   54.73 (+2.01%)
CGC   2.64 (-6.05%)
T   20.90 (-1.92%)
GE   60.85 (-4.23%)
F   10.85 (-4.15%)
DIS   93.96 (-2.27%)
AMC   12.79 (-5.47%)
PFE   50.71 (-3.06%)
PYPL   71.69 (+0.41%)
NFLX   178.48 (-0.82%)
S&P 500   3,754.18 (-1.86%)
DOW   30,453.70 (-2.07%)
QQQ   279.29 (-1.01%)
AAPL   138.42 (-0.37%)
MSFT   256.22 (-1.29%)
META   161.37 (+0.84%)
GOOGL   2,169.75 (-0.23%)
AMZN   110.10 (+0.49%)
TSLA   662.13 (-2.88%)
NVDA   144.95 (-0.19%)
NIO   21.24 (-0.56%)
BABA   114.64 (-1.17%)
AMD   73.14 (-0.72%)
MU   54.73 (+2.01%)
CGC   2.64 (-6.05%)
T   20.90 (-1.92%)
GE   60.85 (-4.23%)
F   10.85 (-4.15%)
DIS   93.96 (-2.27%)
AMC   12.79 (-5.47%)
PFE   50.71 (-3.06%)
PYPL   71.69 (+0.41%)
NFLX   178.48 (-0.82%)
S&P 500   3,754.18 (-1.86%)
DOW   30,453.70 (-2.07%)
QQQ   279.29 (-1.01%)
AAPL   138.42 (-0.37%)
MSFT   256.22 (-1.29%)
META   161.37 (+0.84%)
GOOGL   2,169.75 (-0.23%)
AMZN   110.10 (+0.49%)
TSLA   662.13 (-2.88%)
NVDA   144.95 (-0.19%)
NIO   21.24 (-0.56%)
BABA   114.64 (-1.17%)
AMD   73.14 (-0.72%)
MU   54.73 (+2.01%)
CGC   2.64 (-6.05%)
T   20.90 (-1.92%)
GE   60.85 (-4.23%)
F   10.85 (-4.15%)
DIS   93.96 (-2.27%)
AMC   12.79 (-5.47%)
PFE   50.71 (-3.06%)
PYPL   71.69 (+0.41%)
NFLX   178.48 (-0.82%)
S&P 500   3,754.18 (-1.86%)
DOW   30,453.70 (-2.07%)
QQQ   279.29 (-1.01%)
AAPL   138.42 (-0.37%)
MSFT   256.22 (-1.29%)
META   161.37 (+0.84%)
GOOGL   2,169.75 (-0.23%)
AMZN   110.10 (+0.49%)
TSLA   662.13 (-2.88%)
NVDA   144.95 (-0.19%)
NIO   21.24 (-0.56%)
BABA   114.64 (-1.17%)
AMD   73.14 (-0.72%)
MU   54.73 (+2.01%)
CGC   2.64 (-6.05%)
T   20.90 (-1.92%)
GE   60.85 (-4.23%)
F   10.85 (-4.15%)
DIS   93.96 (-2.27%)
AMC   12.79 (-5.47%)
PFE   50.71 (-3.06%)
PYPL   71.69 (+0.41%)
NFLX   178.48 (-0.82%)
NASDAQ:GMDA

Gamida Cell Stock Forecast, Price & News

$1.88
+0.14 (+8.05%)
(As of 07/5/2022 11:04 AM ET)
Add
Compare
Today's Range
$1.71
$1.89
50-Day Range
$1.73
$2.72
52-Week Range
$1.67
$6.41
Volume
1,749 shs
Average Volume
294,324 shs
Market Capitalization
$111.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.83

Gamida Cell MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
635.8% Upside
$13.83 Price Target
Short Interest
Bearish
6.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Gamida Cell in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.22) to ($1.05) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.81 out of 5 stars

Medical Sector

732nd out of 1,428 stocks

Biological Products, Except Diagnostic Industry

120th out of 218 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

Gamida Cell logo

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

GMDA Stock News Headlines

Gamida Cell Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GMDA
Fax
N/A
Employees
166
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/05/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$13.83
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+635.8%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-89,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.74 per share

Miscellaneous

Free Float
57,661,000
Market Cap
$111.30 million
Optionable
Not Optionable
Beta
1.83














Gamida Cell Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Gamida Cell stock.
View analyst ratings for Gamida Cell
or view top-rated stocks.

What is Gamida Cell's stock price forecast for 2022?

6 brokers have issued 12-month price objectives for Gamida Cell's shares. Their GMDA stock forecasts range from $6.00 to $22.00. On average, they expect Gamida Cell's stock price to reach $13.83 in the next year. This suggests a possible upside of 635.8% from the stock's current price.
View analysts' price targets for Gamida Cell
or view top-rated stocks among Wall Street analysts.

How has Gamida Cell's stock performed in 2022?

Gamida Cell's stock was trading at $2.54 at the beginning of the year. Since then, GMDA shares have decreased by 26.0% and is now trading at $1.88.
View the best growth stocks for 2022 here
.

When is Gamida Cell's next earnings date?

Gamida Cell is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for Gamida Cell
.

How were Gamida Cell's earnings last quarter?

Gamida Cell Ltd. (NASDAQ:GMDA) issued its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.34). During the same period in the previous year, the firm posted ($0.34) earnings per share.
View Gamida Cell's earnings history
.

Who are Gamida Cell's key executives?

Gamida Cell's management team includes the following people:
  • Dr. Julian Adams Ph.D., CEO & Director (Age 67, Pay $707k)
  • Mr. Shai Lankry CPA, M.B.A., Chief Financial Officer (Age 46, Pay $564k)
  • Ms. Michele Ilene Korfin M.B.A., R.Ph., Chief Operating & Chief Commercial Officer (Age 50, Pay $510k)
  • Dr. Ronit Simantov M.D., Chief Medical & Chief Scientific Officer (Age 57, Pay $581k)
  • Dr. Jas Uppal, Chief Regulatory & Quality Officer (Age 54, Pay $476k)
  • Mr. Joshua F. Patterson, Gen. Counsel & Chief Compliance Officer (Age 46)
  • Mr. Paul Nee, VP of Marketing
  • Mr. Naftali Brikashvili CPA, Sr. VP Fin. & Operations
  • Dr. Tracey Lodie Ph.D., Scientific Advisor & Consultant (Age 52)
  • Mr. Vladimir Melnikov, Sr. VP of Global Operations & Manufacturing

What other stocks do shareholders of Gamida Cell own?

When did Gamida Cell IPO?

(GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?

Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."

How do I buy shares of Gamida Cell?

Shares of GMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gamida Cell's stock price today?

One share of GMDA stock can currently be purchased for approximately $1.88.

How much money does Gamida Cell make?

Gamida Cell (NASDAQ:GMDA) has a market capitalization of $111.30 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Gamida Cell have?

Gamida Cell employs 166 workers across the globe.

How can I contact Gamida Cell?

Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for Gamida Cell is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.